An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma

被引：5

作者：

Moreau, Philippe ^{[1
]}

Mateos, Maria-Victoria ^{[2
]}

Blade, Joan ^{[3
]}

Benboubker, Lotfi ^{[4
]}

de la Rubia, Javier ^{[5
,6
]}

Facon, Thierry ^{[7
]}

Comenzo, Raymond L. ^{[8
]}

Fay, Joseph W. ^{[9
]}

Qin, Xiang ^{[10
]}

Masterson, Tara ^{[10
]}

Schecter, Jordan ^{[11
]}

Ahmadi, Tahamtan ^{[10
]}

San Miguel, Jesus ^{[12
]}

机构：

[1] Univ Hosp Nantes, Nantes, France

[2] Univ Hosp Salamanca IBSAL, Salamanca, Spain

[3] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[4] Hop Bretonneau, CHU Tours, Tours, France

[5] Hosp La Fe, E-46009 Valencia, Spain

[6] Univ Catolica San Vicente Martir, Valencia, Spain

[7] CHRU Lille, F-59037 Lille, France

[8] Tufts Med Ctr, Boston, MA USA

[9] Baylor Inst Immunol Res, Dallas, TX USA

[10] Janssen Pharmaceut Res & Dev, Spring House, PA USA

[11] Janssen Pharmaceut Res & Dev, Raritan, NJ USA

[12] Univ Navarra Clin, Pamplona, Spain

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

10.1182/blood.V124.21.3359.3359

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] AN OPEN-LABEL, MULTICENTER, PHASE 1B STUDY OF DARATUMUMAB IN COMBINATION WITH POMALIDOMIDE-DEXAMETHASONE AND WITH BACKBONE REGIMENS IN PATIENTS WITH MULTIPLE MYELOMA
Mateos, M. V.
Moreau, P.
Comenzo, R.
Blade, J.
Benboubker, L.
de la Rubia, J.
Facon, T.
Fay, J.
Qin, X.
Masterson, T.
Schecter, J.
Ahmadi, T.
San-Miguel, J.
[J]. HAEMATOLOGICA, 2015, 100 : 84 - 84
[2] An open-label, multicenter, phase Ib study of daratumumab in combination with backbone regimens in patients with multiple myeloma
Comenzo, Raymond
Moreau, Philippe
Mateos, Maria-Victoria
Blade, Joan
Benboubker, Lotfi
de la Rubia, Javier
Facon, Thierry
Fay, Joseph
Qin, Xiang
Masterson, Tara
Schecter, Jordan
Ahmadi, Tahamtan
San-Miguel, Jesus
[J]. CANCER RESEARCH, 2015, 75
[3] Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study
Lonial, Sagar
San-Miguel, Jesus F.
Martinez-Lopez, Joaquin
Mateos, Maria-Victoria
Blade, Joan
Benboubker, Lotfi
Oriol, Albert
Arnulf, Bertrand
Chari, Ajai
Pineiro, Luis
Wu, Kaida
Wang, Jianping
Doshi, Parul
Schecter, Jordan
Moreau, Philippe
[J]. BLOOD, 2017, 130
[4] SUBCUTANEOUS DARATUMUMAB IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE 1B STUDY (PAVO)
Mateos, M., V
Chari, A.
Nah, H.
Lokhorst, H.
Kaufman, J. L.
Moreau, P.
Oriol, A.
Plesner, T.
Benboubker, L.
Hellemans, P.
Masterson, T.
Clemens, P. L.
Liu, K.
San-Miguel, J.
Usmani, S. Z.
[J]. HAEMATOLOGICA, 2018, 103 : 32 - 33
[5] Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma
Chari, Ajai
Lonial, Sagar
Suvannasankha, Attaya
Fay, Joseph W.
Arnulf, Bertrand
Ifthikharuddin, Jainulabdeen J.
Qin, Xiang
Masterson, Tara
Nottage, Kerri
Schecter, Jordan M.
Ahmadi, Tahamtan
Weiss, Brendan
Krishnan, Amrita
Lentzsch, Suzanne
[J]. BLOOD, 2015, 126 (23)
[6] Subcutaneous (SC) Daratumumab (DARA) in Combination With Standard Multiple Myeloma (MM) Treatment Regimens: An Open-label, Multicenter Phase 2 Study (PLEIADES)
Chari, Ajai
Goldschmidt, Hartmut
San-Miguel, Jesus
McCarthy, Helen
Suzuki, Kenshi
Hungria, Vania
Sureda Balari, Anna
Perrot, Aurore
Hulin, Cyrille
Magen, Hila
Iida, Shinsuke
Maisnar, Vladimir
Karlin, Lionel
Pour, Ludek
Parasrampuria, Dolly
Masterson, Tara
Kosh, Michele
Yang, Shiyi
Qi, Ming
Carson, Robin
Moreau, Philippe
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E16 - E17
[7] Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)
Chari, Ajai
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Kaufman, Jonathan L.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Benboubker, Lotfi
Nahi, Hareth
Tang, Jie
Hellemans, Peter
Tromp, Brenda
Clemens, Pamela L.
Farnsworth, Andrew
San-Miguel, Jesus F.
Usmani, Saad Z.
[J]. BLOOD, 2018, 132
[8] Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)
Usmani, Saad Z.
Nahi, Hareth
Mateos, Maria-Victoria
Lokhorst, Henk M.
Chari, Ajai
Kaufman, Jonathan L.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Benboubker, Lotfi
Hellemans, Peter
Masterson, Tara
Clemens, Pamela L.
Ahmadi, Tahamtan
Liu, Kevin
San-Miguel, Jesus
[J]. BLOOD, 2016, 128 (22)
[9] Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study
Chari, Ajai
Nahi, Hareth
Mateos, Maria-Victoria
Lokhorst, Henk M.
Kaufman, Jonathan L.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Benboubker, Lotfi
Hellemans, Peter
Masterson, Tara
Clemens, Pamela L.
Liu, Kevin
San-Miguel, Jesus F.
Usmani, Saad Z.
[J]. BLOOD, 2017, 130
[10] Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study
Nahi, Hareth
Usmani, Saad Z.
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Bandyopadhyay, Nibedita
Hellemans, Peter
Tromp, Brenda
Nnane, Ivo
Zemlickis, Donna
Farnsworth, Andrew
Chari, Ajai
[J]. BLOOD, 2021, 138

← 1 2 3 4 5 →